Platelet Counting and Interference Patents: Filing Trends and Leading Assignees
48.3% concentration. The top 5 of 85 ranked assignees account for 143 of 296 records in scope — near half the field sits with a handful of filers. Annual filings rose from 9 in 2017 to a peak of 30 in 2023, then the 2021-to-2024 comparison shows a -100% change. Treat 2025 and 2026 as incomplete rather than as evidence of a real decline — publication typically lags filing by around 18 months, so the most recent two years will keep filling in.
- 1HAEMOSTATIX LTD43
- 2ALERE SAN DIEGO INC35
- 3T2 BIOSYSTEMS INC30
- 4ALEXION PHARMACEUTICALS INC19
- 5ABBOTT POINT OF CARE INC16
See the full platelet counting and interference analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who are the leading patent holders in platelet counting and interference technology?
The dataset ranks 85 assignees across 296 records, with a clear leader holding 43 records — more than double the fifth-place holder's 16. The top 5 assignees together account for 48.3% of all records in scope, and the top 10 account for 70.9%, so concentration is high at the very top even though the full ranking runs to 85 companies. Beyond the top 10, portfolios thin out quickly into single-digit counts, which is typical of a field with a few dominant instrument and diagnostics makers plus many smaller biomarker-focused filers.
Is patent filing in this space growing or slowing down?
Filing rose from 9 records in 2017 to a peak of 30 in 2023, and the 2021-to-2024 comparison shows a -100% change over that span. However, patent publication typically lags actual filing by around 18 months, so the 2025 and 2026 counts in any dataset with a mid-2026 cut-off are still incomplete. The honest read is that the field peaked in 2023 and the most recent years cannot yet be judged as rising or falling.
Which technology areas are most crowded and which are open?
G01N (material analysis and testing) appears in 53.0% of the 296 records and A61K (medicinal preparations) in 42.9%, making assay chemistry and marker/therapeutic claims the densest part of the landscape. A61M (devices for body fluids) at 6.4% and G01R (electric and magnetic measurement) at 3.4% are comparatively open, suggesting the physical instrumentation and point-of-care device layer carries fewer competing claims than the underlying assay science.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Platelet Counting and Interference covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.